AN2 THERAPEUTICS
AN2 Therapeutics, Inc. is a California-based global health biopharmaceutical company focused on modern biomedical and drug development expertise to provide transformational medicines for patients suffering from infectious diseases. The company was founded in 2017 and is headquartered in Menlo Park, California, United States.
AN2 THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2017-01-01
Address:
Menlo Park, California, United States
Country:
United States
Website Url:
http://www.an2therapeutics.com
Total Employee:
11+
Status:
Active
Total Funding:
162 M USD
Technology used in webpage:
IPv6 Akamai Hosted
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Grant - AN2 Therapeutics
Adage Capital Management
Adage Capital Management investment in Post-IPO Equity - AN2 Therapeutics
RA Capital Management
RA Capital Management investment in Post-IPO Equity - AN2 Therapeutics
Avidity Partners
Avidity Partners investment in Post-IPO Equity - AN2 Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Post-IPO Equity - AN2 Therapeutics
TCG Crossover
TCG Crossover investment in Post-IPO Equity - AN2 Therapeutics
Frazier Life Sciences
Frazier Life Sciences investment in Post-IPO Equity - AN2 Therapeutics
Marshall Wace
Marshall Wace investment in Post-IPO Equity - AN2 Therapeutics
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - AN2 Therapeutics
Avidity Partners
Avidity Partners investment in Series B - AN2 Therapeutics
Official Site Inspections
http://www.an2therapeutics.com Semrush global rank: 4.1 M Semrush visits lastest month: 2.54 K
- Host name: ec2-34-192-255-123.compute-1.amazonaws.com
- IP address: 34.192.255.123
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "AN2 Therapeutics"
AN2 Therapeutics - Crunchbase Company Profile
AN2 Therapeutics, Inc. is a California-based global health biopharmaceutical company focused on modern biomedical and drug development expertise to …See details»
AN2 Therapeutics - LinkedIn
AN2 Therapeutics, Inc. is a biopharmaceutical company dedicated to developing therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet needs.See details»
AN2 Therapeutics - PitchBook
AN2 Therapeutics General Information Description. AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived …See details»
AN2 Therapeutics (ANTX) Company Profile & Description - Stock …
Mar 25, 2022 AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company’s initial candidate includes …See details»
AN2 Therapeutics: Contact Details, Revenue, Funding, Employees …
AN2 Therapeutics is a biopharmaceutical company focused on developing therapies for rare, chronic, and serious infectious diseases in areas with high unmet medical needs, leveraging …See details»
An2 Therapeutics, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for An2 Therapeutics, Inc. of Menlo Park, CA. Get the latest business insights from Dun & Bradstreet.See details»
AN2 Therapeutics Company Profile - Office Locations ... - Craft
Oct 29, 2024 AN2 Therapeutics has 1 employees at their 1 location. See insights on AN2 Therapeutics including office locations, competitors, revenue, financials, executives, …See details»
AN2 Therapeutics Information - RocketReach
Founded by a team of experienced industry leaders in infectious disease drug research and development and boron chemistry, we have a passion for addressing the challenges of …See details»
AN2 Therapeutics to Present at Leerink Partners Global Healthcare ...
Mar 3, 2025 MENLO PARK, Calif.--(BUSINESS WIRE)--Mar. 3, 2025-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel …See details»
AN2 Therapeutics | Developing Therapies for Rare, Chronic, and …
At AN2 Therapeutics our mission is to develop therapeutics to treat rare, chronic, and serious infectious disease in areas of high unmet medical need.See details»
AN2 Therapeutics - Overview, News & Similar companies - ZoomInfo
May 15, 2024 AN2 Therapeutics contact info: Phone number: (650) 331-9090 Website: www.an2therapeutics.com What does AN2 Therapeutics do? AN2 Therapeutics, Inc. is a …See details»
AN2 Therapeutics - VentureRadar
"AN2 Therapeutics, Inc. is a California-based global health biopharmaceutical company focused on bringing the power of modern biomedical and drug development expertise to create …See details»
AN2 Therapeutics Closed $80 Million Series B Financing
Jan 7, 2022 AN2 is developing epetraborole, a once-daily oral investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM). For more …See details»
AN2 Therapeutics to Participate at Upcoming Investor Conferences
Nov 14, 2024 For more information, please visit our website at www.an2therapeutics.com. Contacts. COMPANY CONTACT: Lucy O. Day Chief Financial Officer …See details»
Investors - AN2 Therapeutics, Inc
Sep 26, 2023 Grant from Bill & Melinda Gates Foundation. MENLO PARK, Calif.--(BUSINESS WIRE)--Sep. 26, 2023-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage …See details»
AN2 Therapeutics Reports First Quarter 2025 Financial ... - BioSpace
2 days ago Cash, cash equivalents, and investments of $78.5 million at March 31, 2025 and cash runway anticipated to fund operations into 2028. MENLO PARK, Calif.--(BUSINESS …See details»
Latest News | Media Contact - AN2 Therapeutics
Nov 21, 2019 Latest News for AN2 Therapeutics, developing therapeutics to treat rare, chronic, and serious infectious disease in areas of high unmet medical need.See details»
AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 …
Dec 31, 2024 These filings, when made, are available on the investor relations section of AN2’s website at www.an2therapeutics.com and on the SEC’s website at www.sec.gov. Forward …See details»
Development Pipeline - AN2 Therapeutics
About AN2-502998. AN2-502998 (formerly known as AN15368) is a boron-based small molecule therapeutic candidate under development for the treatment of chronic Trypanosoma cruzi (T. …See details»
AN2 Therapeutics Provides Regulatory Update
Jan 20, 2022 AN2 Therapeutics Provides Regulatory Update and Plan to Initiate Clinical Development for Epetraborole Targeting NTM Lung DiseaseSee details»